New topical drug could tackle stubborn toenail fungus
NCT ID NCT07065773
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a topical solution called Trichostatin A for mild-to-severe toenail fungus (onychomycosis). About 50 adults with a confirmed fungal infection will apply the drug daily for 4 weeks. Researchers will check safety and whether the fungus clears up using lab tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Trichostatin A (topical solution)
- What this could lead to
- If successful, this could provide a new topical treatment option for stubborn toenail fungus infections.
- What could go wrong
- This is an early Phase 2 study with only 50 participants, so results may not apply broadly. The treatment may not clear the infection or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ONYCHOMYCOSIS OF TOENAIL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vanda Investigational Site
Fremont, California, 94538, United States
-
Vanda Investigational Site
Denver, Colorado, 80210, United States
-
Vanda Investigational Site
New Brighton, Minnesota, 55112, United States
-
Vanda Investigational Site
Pflugerville, Texas, 78660, United States
-
Vanda Investigational Site
Forest, Virginia, 24551, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.